Strides Pharma Science 미래 성장

Future 기준 확인 3/6

Strides Pharma Science (는) 각각 연간 42.1% 및 10% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 42.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.3% 로 예상됩니다.

주요 정보

42.1%

수익 성장률

42.1%

EPS 성장률

Pharmaceuticals 수익 성장	17.5%
매출 성장률	10.0%
향후 자기자본 수익률	18.3%
애널리스트 커버리지	Low
마지막 업데이트	16 Dec 2024

최근 미래 성장 업데이트

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Recent updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Oct 21

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Aug 14

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15

수익 및 매출 성장 예측

NSEI:STAR - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	56,068	6,443	8,864	8,864	3
3/31/2026	50,121	5,085	7,836	8,254	4
3/31/2025	44,973	3,705	6,375	6,375	4
9/30/2024	44,103	1,771	6,344	8,172	N/A
6/30/2024	42,086	-475	N/A	N/A	N/A
3/31/2024	40,511	-1,248	5,829	7,011	N/A
12/31/2023	39,535	-1,525	N/A	N/A	N/A
9/30/2023	37,806	-2,280	3,043	3,903	N/A
6/30/2023	36,783	-924	N/A	N/A	N/A
3/31/2023	36,884	-2,212	-505	444	N/A
12/31/2022	35,680	-1,824	N/A	N/A	N/A
9/30/2022	34,976	-2,241	-2,101	-1,144	N/A
6/30/2022	33,220	-3,909	N/A	N/A	N/A
3/31/2022	30,703	-4,602	-4,012	-2,578	N/A
12/31/2021	31,127	-4,425	N/A	N/A	N/A
9/30/2021	31,504	-2,830	-1,188	1,572	N/A
6/30/2021	32,224	-543	N/A	N/A	N/A
3/31/2021	33,159	2,545	1,840	4,814	N/A
12/31/2020	30,260	28	N/A	N/A	N/A
9/30/2020	29,264	589	970	2,699	N/A
6/30/2020	28,480	1,266	N/A	N/A	N/A
3/31/2020	27,520	492	548	2,048	N/A
12/31/2019	35,828	2,859	N/A	N/A	N/A
9/30/2019	34,203	2,169	-1,519	1,896	N/A
6/30/2019	32,248	745	N/A	N/A	N/A
3/31/2019	21,784	840	-2,690	601	N/A
12/31/2018	28,547	-93	N/A	N/A	N/A
9/30/2018	28,090	139	N/A	N/A	N/A
6/30/2018	28,451	415	N/A	N/A	N/A
3/31/2018	28,451	544	N/A	1,871	N/A
12/31/2017	35,810	1,050	N/A	N/A	N/A
9/30/2017	36,593	1,124	N/A	N/A	N/A
6/30/2017	35,357	1,712	N/A	N/A	N/A
3/31/2017	27,554	2,335	N/A	2,881	N/A
12/31/2016	37,237	2,840	N/A	N/A	N/A
9/30/2016	36,573	2,410	N/A	N/A	N/A
6/30/2016	34,189	2,168	N/A	N/A	N/A
3/31/2016	28,622	1,317	N/A	732	N/A
12/31/2015	24,901	1,152	N/A	N/A	N/A
9/30/2015	12,962	860	N/A	N/A	N/A
6/30/2015	12,105	244	N/A	N/A	N/A
3/31/2015	11,958	16	N/A	834	N/A
3/31/2014	10,728	-1,867	N/A	-2,173	N/A

애널리스트 미래 성장 예측

수입 대 저축률: STAR 의 연간 예상 수익 증가율( 42.1% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: STAR 의 연간 수익( 42.1% ) Indian 시장( 18.1% 보다 빠르게 성장할 것으로 예상됩니다. 18.1% 연간).

고성장 수익: STAR 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: STAR 의 수익(연간 10% ) Indian 시장( 10.5% 보다 느리게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: STAR 의 수익(연간 10% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: STAR 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18.3 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/21 03:48
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Strides Pharma Science Limited 20 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Aditya Khemka	Ambit Capital
Harith Ahamed	Avendus Spark
Prakash Agarwal	Axis Capital Limited

Strides Pharma Science 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Price target increased by 10% to ₹730

Price target increased by 10% to ₹530

Price target decreased by 7.2% to ₹462

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Recent updates

Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited.

New major risk - Share price stability

Now 59% undervalued after recent price drop

Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024

Upcoming dividend of ₹2.50 per share

Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director

First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024)

Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024

Insufficient new directors

New minor risk - Dividend sustainability

Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target increased by 10% to ₹730

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022)

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Now 20% undervalued after recent price drop

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Executive Changes

Founder & Non-Executive Chairman recently bought ₹50m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP